Cerenis Therapeutics is a pharmaceutical company focused on the discovery, development and commercialization of breakthrough HDL-related therapies for the treatment of cardiovascular and metabolic diseases.
Based on breakthrough research in HDL therapy, Cerenis is pursuing a range of HDL product candidates that reflect significant commercial opportunities in the treatment of atherosclerosis.
High-density lipoprotein (HDL), also known as "good" cholesterol, is the primary vehicle for removal of excess cholesterol from the body through a process known as "reverse lipid transport." HDL is an important target area for new therapeutic agents to treat cardiovascular disease, which is the leading killer of men and women in industrialized nations
